|
|
|
June 15, 2009 APF530 is undergoing regulatory review for a new drug approval for the prevention of chemotherapy-induced nausea and vomiting, according to manufacturer A.P. Pharma. PF530 is a formulation of granisetron, a 5-HT3 antagonist. More »June 15, 2009 ORLANDO—Ginger has been used for years to treat gastrointestinal upset, but for the first time, a large double-blind multicenter randomized study has shown ginger supplements can successfully stem chemotherapy-related nausea, University of Rochester in New York investigators reported at ASCO 2009 (abstract 9511). Some 70% of patients experience nausea and vomiting related to chemotherapy. While vomiting can largely be prevented with anti-emetics, nausea is typically more difficult to prevent and... More »December 1, 2008 Sancuso (granisetron transdermal system) is now available by prescription in the U.S. for patients with chemotherapyinduced nausea and vomiting. The patch continuously releases granisetron into the bloodstream for up to five consecutive days. More »September 1, 2008 The US Food and Drug Administration (FDA) has approved a new oral formulation of palonosetron hydrochloride (Aloxi) for the prevention of chemotherapy-induced nausea and vomiting (CINV). Oral administration of palonosetron capsules is indicated for the prevention of acute nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A single 0.5-mg palonosetron capsule is administered approximately 1 hour prior to the start of chemotherapy. More »February 1, 2008 A 22-year-old woman has had chronic nausea, emesis with green vomitus, and diarrhea for the past 10 months. The diarrhea is frequent (about 3 to 8 times daily) and does not resolve with starvation. More »November 1, 2007 A 44-year-old man presents to the emergency department (ED) with light-headedness, nausea, and vomiting of 1 day's duration. He has also had intermittent palpitations but denies chest pain, dyspnea, and weakness. More »July 1, 2007 A review of "Chemotherapy-Induced Nausea and Vomiting: Which Antiemetic for Which Therapy?" More »July 1, 2007 A review of "Chemotherapy-Induced Nausea and Vomiting: Which Antiemetic for Which Therapy?" More »July 1, 2007 Chemotherapy-induced nausea and vomiting (CINV) remains an important and common toxicity of cancer treatment. Recent guideline revisions have classified chemotherapeutic agents into four categories of emesis risk without the use of preventive agents: high (> 90%), moderate (30%-90%), low (10%-30%), and minimal (< 10%). Currently available antiemetic agents, including corticosteroids, 5-hydroxytryptamine (HT)3 receptor antagonists, and neurokinin (NK)-1 antagonists are used alone or in... More »July 1, 2007 A review of "Chemotherapy-Induced Nausea and Vomiting: Which Antiemetic for Which Therapy?" More »
Showing 1 - 10 of 30 results.
|
|
Understanding and Treating Triple-Negative Breast Cancer
ONCOLOGY, October 1, 2008
Rising PSA in Nonmetastatic Prostate Cancer
ONCOLOGY, November 1, 2007
Breast Cancer in Women Under 40
ONCOLOGY, May 14, 2009
Anthracycline Cardiotoxicity After Breast Cancer Treatment
ONCOLOGY, March 16, 2009
Predicting Endocrine Therapy Responsiveness in Breast Cancer
ONCOLOGY, February 18, 2009
|
SearchMedica Search Result
Find peer-reviewed literature and websites for practicing medical professionals
|
|
|
|
|
|
